Pfizer has launched its programme on TrumpRx, making innovative medicines more affordable and accessible. The programme provides Americans over 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favoured Nation (MFN) agreement with the US government enabling patients to pay lower prices for their prescription medicines, while strengthening America’s role as a global leader in pharmaceutical innovation.

“For far too long, Americans have shouldered a disproportionate share of the global cost of innovation to help develop breakthroughs for the entire world. As the first pharmaceutical company to support President Trump in addressing this imbalance, we’re proud to continue to work with the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Through the TrumpRx platform, uninsured or insured American patients who choose to self-pay outside of insurance will be offered savings that range as high as 85 pefrcent, and on average 50 percent, for the large majority of Pfizer’s primary care treatments and select specialty brands. This allows American consumers to choose what best fits their needs without hassle. More than 100 million patients are impacted by diseases these medicines treat – such as migraines, rheumatoid arthritis, menopause, atopic dermatitis, overactive bladder – and those patients will now have access to significantly discounted medicines.

Pfizer is partnering closely with GoodRx enabling patients seeking affordable treatments to have greater flexibility and options, including the ability to use a coupon at almost any US pharmacy or select at-home delivery.

Pfizer will also continue to expand PfizerForAll, a direct-to-consumer platform launched in 2024, to offer more ways for people – and not middlemen – to be in charge of their healthcare.